| Literature DB >> 26401844 |
Radka Saldova1, Henning Stöckmann1, Roisin O'Flaherty1, Dirk J Lefeber2, Jaak Jaeken3, Pauline M Rudd1.
Abstract
MAN1B1-CDG has recently been characterized as a type II congenital disorder of glycosylation (CDG), disrupting not only protein N-glycosylation but also general Golgi morphology. Using our high-throughput, quantitative ultra-performance liquid chromatography assay, we achieved a detailed characterization of the glycosylation changes in both total serum glycoproteins and isolated serum IgG from ten previously reported MAN1B1-CDG patients. We have identified and quantified novel hybrid high-mannosylated MAN1B1-CDG-specific IgG glycans and found an increase of sialyl Lewis x (sLex) glycans on serum proteins of all patients. This increase in sLex has not been previously reported in any CDG. These findings may provide insight into the pathophysiology of this CDG.Entities:
Keywords: CDG; IgG; MAN1B1; N-glycans; biomarkers; glycomics; human serum; sialyl Lewis x; ultra performance liquid chromatography
Mesh:
Substances:
Year: 2015 PMID: 26401844 DOI: 10.1021/acs.jproteome.5b00709
Source DB: PubMed Journal: J Proteome Res ISSN: 1535-3893 Impact factor: 4.466